Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.37 |
| ▸ | F10 | P00742 | 10/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | FPR1 | P21462 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068362 | 0.87 | CNR2 (0.40) | ALOX5APFEN1DDB1CRBNCNR2 | |
| SCHEMBL29348659 | 0.87 | DDB1 (0.35) | DDB1CRBNF10FPR1FPR2 | |
| SCHEMBL29348645 | 0.87 | CRBN (0.39) | DDB1CRBNF10 | |
| SCHEMBL29348585 | 0.87 | CNR2 (0.40) | ALOX5APFEN1DDB1CRBNCNR2 | |
| SCHEMBL29348285 | 0.85 | DDB1 (0.41) | DDB1CRBNF10CNR2IKZF3 | |
| SCHEMBL29348568 | 0.84 | DDB1 (0.36) | DDB1CRBNIKZF3 | |
| SCHEMBL29348393 | 0.82 | CNR2 (0.42) | DDB1CRBNCNR2IKZF3 | |
| SCHEMBL31068267 | 0.81 | CNR2 (0.59) | DDB1CRBNCNR2 | |
| SCHEMBL29348994 | 0.81 | CNR2 (0.59) | DDB1CRBNCNR2 | |
| SCHEMBL29348669 | 0.81 | CRBN (0.40) | DDB1CRBNIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | ALOX5AP 3723/4885FEN1 2128/4885DDB1 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.